- Home
- RARE vs SRRK Comparison
RARE vs SRRK Comparison
Compare RARE & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- SRRK
- Stock Information
- Founded
- RARE 2010
- SRRK 2012
- Country
- RARE United States
- SRRK United States
- Employees
- RARE N/A
- SRRK N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RARE Health Care
- SRRK Health Care
- Exchange
- RARE Nasdaq
- SRRK Nasdaq
- Market Cap
- RARE 3.3B
- SRRK 2.8B
- IPO Year
- RARE 2014
- SRRK 2018
- Fundamental
- Price
- RARE $37.17
- SRRK $34.23
- Analyst Decision
- RARE Strong Buy
- SRRK Strong Buy
- Analyst Count
- RARE 17
- SRRK 6
- Target Price
- RARE $92.29
- SRRK $42.17
- AVG Volume (30 Days)
- RARE 974.0K
- SRRK 1.1M
- Earning Date
- RARE 07-31-2025
- SRRK 05-14-2025
- Dividend Yield
- RARE N/A
- SRRK N/A
- EPS Growth
- RARE N/A
- SRRK N/A
- EPS
- RARE N/A
- SRRK N/A
- Revenue
- RARE $590,689,000.00
- SRRK N/A
- Revenue This Year
- RARE $18.94
- SRRK N/A
- Revenue Next Year
- RARE $28.93
- SRRK $312.40
- P/E Ratio
- RARE N/A
- SRRK N/A
- Revenue Growth
- RARE 33.46
- SRRK N/A
- 52 Week Low
- RARE $29.59
- SRRK $6.76
- 52 Week High
- RARE $60.37
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- RARE 55.64
- SRRK 62.26
- Support Level
- RARE $35.73
- SRRK $30.36
- Resistance Level
- RARE $36.22
- SRRK $31.60
- Average True Range (ATR)
- RARE 1.37
- SRRK 1.82
- MACD
- RARE 0.25
- SRRK 0.46
- Stochastic Oscillator
- RARE 90.54
- SRRK 79.73
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.